EE200300017A - Otsese pressimisega saadud tablett, mis sisaldab toimeainena 4-amino-1-hüdroksübutülideen-1,1-bisfosfoonhapet - Google Patents

Otsese pressimisega saadud tablett, mis sisaldab toimeainena 4-amino-1-hüdroksübutülideen-1,1-bisfosfoonhapet

Info

Publication number
EE200300017A
EE200300017A EEP200300017A EEP200300017A EE200300017A EE 200300017 A EE200300017 A EE 200300017A EE P200300017 A EEP200300017 A EE P200300017A EE P200300017 A EEP200300017 A EE P200300017A EE 200300017 A EE200300017 A EE 200300017A
Authority
EE
Estonia
Prior art keywords
hydroxybutylidene
amino
active ingredient
direct compression
tablet containing
Prior art date
Application number
EEP200300017A
Other languages
English (en)
Inventor
Jasprov� Dagmar
Original Assignee
L�civa, a.s.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5471285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200300017(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by L�civa, a.s. filed Critical L�civa, a.s.
Publication of EE200300017A publication Critical patent/EE200300017A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200300017A 2000-07-11 2001-06-29 Otsese pressimisega saadud tablett, mis sisaldab toimeainena 4-amino-1-hüdroksübutülideen-1,1-bisfosfoonhapet EE200300017A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20002567A CZ20002567A3 (cs) 2000-07-11 2000-07-11 Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby
PCT/CZ2001/000037 WO2002003963A1 (en) 2000-07-11 2001-06-29 Tablet obtained by direct compression comprising 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid as active ingredient

Publications (1)

Publication Number Publication Date
EE200300017A true EE200300017A (et) 2004-10-15

Family

ID=5471285

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300017A EE200300017A (et) 2000-07-11 2001-06-29 Otsese pressimisega saadud tablett, mis sisaldab toimeainena 4-amino-1-hüdroksübutülideen-1,1-bisfosfoonhapet

Country Status (17)

Country Link
US (1) US7198802B2 (et)
EP (1) EP1299088B1 (et)
AT (1) ATE331502T1 (et)
AU (1) AU2001270454A1 (et)
BG (1) BG107520A (et)
CA (1) CA2415630A1 (et)
CZ (1) CZ20002567A3 (et)
DE (1) DE60121166D1 (et)
EE (1) EE200300017A (et)
HR (1) HRP20020735A2 (et)
HU (1) HUP0301072A3 (et)
PL (1) PL360872A1 (et)
RU (1) RU2279273C2 (et)
SK (1) SK283249B6 (et)
UA (1) UA73784C2 (et)
WO (1) WO2002003963A1 (et)
YU (1) YU77702A (et)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6827718B2 (en) 2001-08-14 2004-12-07 Scimed Life Systems, Inc. Method of and apparatus for positioning and maintaining the position of endoscopic instruments
CA2481091A1 (en) * 2002-04-05 2003-10-23 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
GR1004331B (el) * 2002-10-07 2003-09-05 Verisfield (Uk) Ltd Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος
EP1781258A1 (en) * 2004-08-20 2007-05-09 Mepha AG Formulations of bisphosphonates
WO2006046100A1 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Pharmaceutical composition of alendronic acid
WO2006054165A1 (en) * 2004-11-19 2006-05-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of alendronic acid and processes for their preparation
JP5424642B2 (ja) * 2005-10-27 2014-02-26 ニクリス アーゲー インプラント及びその製造方法
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
MX2011002016A (es) * 2008-08-22 2011-05-19 Wockhardt Research Center Composición farmacéutica de dosis oral en una sola unidad, que comprende levodopa, carbidopa y entacapona, o sales.
EA201190243A1 (ru) * 2009-05-19 2013-01-30 Гриндекс, Э Джоинт Сток Кампани Стабильная фармацевтическая композиция флударабина фосфата
US10071059B2 (en) 2009-12-18 2018-09-11 Frieslandcampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
CN117835971A (zh) 2021-08-25 2024-04-05 巴斯夫欧洲公司 直接压片用辅料组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
DE59300688D1 (de) * 1993-05-15 1995-11-02 Boehringer Mannheim Gmbh Tablette mit verbesserter Bioverfügbarkeit enthaltend Dichlormethylendiphosphonsäure als Wirkstoff.
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
NZ527200A (en) 1997-03-26 2004-12-24 Sepracor Inc Stable norastemizole formulations including a super disintegrant
BR0109838A (pt) * 2000-04-07 2003-01-21 Pfizer Prod Inc Metabólitos de agonista/antagonista de estrogênio

Also Published As

Publication number Publication date
RU2279273C2 (ru) 2006-07-10
CZ289261B6 (cs) 2001-12-12
AU2001270454A1 (en) 2002-01-21
HUP0301072A3 (en) 2005-07-28
EP1299088B1 (en) 2006-06-28
CA2415630A1 (en) 2002-01-17
PL360872A1 (en) 2004-09-20
SK5112001A3 (en) 2002-02-05
UA73784C2 (en) 2005-09-15
DE60121166D1 (de) 2006-08-10
SK283249B6 (sk) 2003-04-01
YU77702A (sh) 2006-05-25
US20030161878A1 (en) 2003-08-28
WO2002003963A1 (en) 2002-01-17
CZ20002567A3 (cs) 2001-12-12
US7198802B2 (en) 2007-04-03
BG107520A (bg) 2003-06-30
EP1299088A1 (en) 2003-04-09
HUP0301072A2 (hu) 2003-08-28
HRP20020735A2 (en) 2004-12-31
ATE331502T1 (de) 2006-07-15

Similar Documents

Publication Publication Date Title
RS50876B (sr) Upotreba flibanserina u lečenju seksualnih poremećaja
TW200505406A (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
PT1379520E (pt) Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b
NZ507271A (en) Fast disintegrating tablets
EE200300017A (et) Otsese pressimisega saadud tablett, mis sisaldab toimeainena 4-amino-1-hüdroksübutülideen-1,1-bisfosfoonhapet
PE20001036A1 (es) Tabletas bioadhesivas para hidratacion progresiva y metodos para su elaboracion y uso
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
EA200000584A2 (ru) Твердые фармацевтические композиции с контролируемым высвобождением, получаемые тепловым формованием
DE60142891D1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
JP2002511411A5 (et)
ES2082723B1 (es) Formulacion farmaceutica de fluoxetina en forma dispersable.
MXPA02003203A (es) Composiciones terapeuticas solubles en tocol.
DE60019693D1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
HRP20040996B1 (en) High drug load tablet
MXPA04005105A (es) Formulaciones de acitromicina directamente compresibles.
RU2003102448A (ru) Таблетка, получаемая непосредственным прессованием, содержащая 4-амино-1-гидроксибутилиден-1,1-бисфосфоновую кислоту в качестве активного ингредиента
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
CA2311024A1 (en) Pharmaceutical composition for oral administration of chelating agents
IT1273790B (it) Derivati eterociclici diazotati aventi attivita' aii antagonista
EP1219296A4 (en) SEBUM PRODUCTION INHIBITORS
WO2002096901A3 (de) 1,3-dihydroxybenzol-derivate und diese verbindungen enthaltende färbemittel
CA2373166A1 (en) Antiulcer agent
RS50288B (sr) Amycomycin, postupak za njegovu proizvodnju i njegova upotreba kao farmaceutika
GT199800008A (es) Procedimiento para la preparacion de un derivado de tetrahidropiridina.